The superiority of targetd therapy compared with chemotherapy make it a star in cancer therapy research. So a lot of researches have been conducted in this area. Many researches have achieved good results and steppped into clinical sections. Furthermore, some of the drugs have been approved by FDA, leading to great significances in cancer therapy.
Elotuzumab, developed Bristol-Myers Squibb of New York, is a humanized monoclonal immunoglobulin G1 antibody targeting SLAMF7, which can be found on the surface of myeloma cells and natural killer lymphocytes in the immune system. It is approved on November 30, 2015 by the U.S. Food and Drug Administration for treating people with multiple myeloma who have received one to three prior medications in combination with two other therapies.
Necitumumab, developed by Eli Lilly, is a recombinant human IgG1 monoclonal antibody that binds to the human epidermal growth factor receptor (EGFR) and blocks the binding of EGFR to its ligands. It is applied in combination with gemcitabine and cisplatin for first-line treatment of patients with metastatic squamous non-small cell lung cancer (NSCLC).
Daratumumab, jointly developed by Genmab along with the Johnson & Johnson subsidiary Janssen Biotech, by bingding to CD38 is the first monoclonal antibody approved for the treatment of multiple myeloma. It is administered as a single agent for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy, including a proteasome inhibitor (PI) and an immunomodulatory agent, or who are double-refractory to a PI and an immunomodulatory agent.
Ramucirumab, developed by Eli Lilly, a recombinant monoclonal antibody of the IgG1 class that binds to vascular endothelial growth factor receptor-2 (VEGFR-2) and blocks the activation of the receptor. It is approved for the treatment of multiple sollid tumors: metastatic colorectal cancer, platinum-resistant metastatic non-small cell lung cancer, advanced gastric or gastroesophageal junction adenocarcinoma and gastric or gastroesophageal junction adenocarcinoma.
Trastuzumab, developed by Genentech, Inc., a monoclonal antibody that interferes with the HER2/neu receptor. It is approved in combination with cisplatin and a fluoropyrimidine (capecitabine or 5-fluorouracil), for the treatment of patients with HER2 overexpressing metastatic gastric or gastroesophageal (GE) junction adenocarcinoma, who have not received prior treatment for metastatic disease.
Vemurafenib, developed by Hoffmann-La Roche Inc., a B-Raf enzyme inhibitor. It is approved for the treatment of patients with unresectable or metastatic melanoma with the BRAF V600E mutation as detected by an FDA-approved test.
Crizotinib, developed by Pfizer, Inc., a targted therapy drug for both ALK and ROS1. It is approved to treat patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive in 2016. And in 2013 it is also indicated for patients with metastatic NSCLC whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test.